40
Participants
Start Date
November 30, 2018
Primary Completion Date
February 19, 2025
Study Completion Date
February 19, 2025
a1DC + inactivated whole autologous HIV
Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
a1DC + conserved HIV peptides
Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
a1DC + no antigen
Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
pgDC + inactivated whole autologous HIV
Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
pgDC + conserved HIV peptides
Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
pgDC + no antigen
Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
HIV/AIDS Clinical Research Unit / University of Pittsburgh, Pittsburgh
AIDS Clinical Trials Unit/The Ohio State University, Columbus
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sharon Riddler
OTHER